Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Advanced Solid Tumors CancerNon Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

ABBV-637

Intravenous (IV) Infusion

DRUG

Docetaxel

Intravenous (IV) Infusion

DRUG

Osimertinib

Oral Tablets

Trial Locations (33)

333

Linkou Chang Gung Memorial Hospital /ID# 225946, Taoyuan

704

National Cheng Kung University Hospital /ID# 225944, Tainan City

807

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 243345, Kaohsiung City

2500

Wollongong Hospital /ID# 228350, Wollongong

3084

Austin Health /ID# 225638, Heidelberg

10408

National Cancer Center /ID# 231887, Goyang-si

13385

AP-HM - Hopital de la Timone /ID# 225779, Marseille

21079

Centre Georges François Leclerc /ID# 226760, Dijon

22031

Virginia Cancer Specialists - Fairfax /ID# 225693, Fairfax

28040

Hospital Universitario Fundacion Jimenez Diaz /ID# 225975, Madrid

28041

Hospital Universitario 12 de Octubre /ID# 225977, Madrid

28078

Carolina BioOncology Institute /ID# 225358, Huntersville

28222

Hospital Universitario Puerta de Hierro - Majadahonda /ID# 226096, Majadahonda

29010

Hospital Universitario Virgen de la Victoria /ID# 225978, Málaga

30059

National Taiwan University Hospital - Hsinchu branch /ID# 243610, Hsinchu

31052

Institut Claudius Regaud /ID# 225780, Toulouse

33000

Institut Bergonie /ID# 225778, Bordeaux

63110

Washington University-School of Medicine /ID# 225698, St Louis

75248

Institut Curie /ID# 225829, Paris

78229

South Texas Accelerated Research Therapeutics /ID# 225359, San Antonio

3109601

Rambam Health Care Campus /ID# 225586, Haifa

5265601

The Chaim Sheba Medical Center /ID# 225585, Ramat Gan

02215

Dana-Farber Cancer Institute /ID# 231209, Boston

02903-4923

Lifespan Cancer Institute at Rhode Island Hospital /ID# 226145, Providence

460-0001

NHO Nagoya Medical Center /ID# 244412, Nagoya

277-8577

National Cancer Center Hospital East /ID# 225725, Kashiwa-shi

791-0280

Duplicate_National Hospital Organization Shikoku Cancer Center /ID# 240821, Matsuyama

811-1395

National Hospital Organization Kyushu Cancer Center /ID# 240761, Fukuoka

104-0045

National Cancer Center Hospital /ID# 225724, Chuo-ku

05505

Asan Medical Center /ID# 231886, Seoul

06351

Samsung Medical Center /ID# 231888, Seoul

03722

Yonsei University Health System Severance Hospital /ID# 233774, Seoul

08035

Hospital Universitario Vall d'Hebron /ID# 225976, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY